Aditxt (NASDAQ:ADTX) announced that a Mayo Clinic study has confirmed ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD)—a key autoantigen connected to multiple autoimmune conditions including Type 1 diabetes, stiff person syndrome, cerebellar ataxia, and autoimmune epilepsy.
According to Aditxt, the independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic’s neuroimmunology team, validated preclinical findings by revealing that ADI-100 demonstrated an encouraging safety profile, immune modulation at the cellular level, and antigen-specific suppression. Adimune, a wholly owned subsidiary of Aditxt, is developing ADI-100.
“These results mark an important milestone not only for Adimune’s platform but also for Aditxt’s broader vision of transforming the way we approach autoimmune diseases,” said Amro Albanna, co-founder and CEO of Aditxt.
“We believe that autoimmunity represents one of the most underserved and challenging areas of medicine. ADI-100’s potential ability to restore immune tolerance without broad immunosuppression is a meaningful step toward safer, more targeted treatments,” he added.
